Dyne Therapeutics, Inc. (DYN)

Market Cap	1.30B
Revenue (ttm)	n/a
Net Income (ttm)	-317.42M
Shares Out	113.12M
EPS (ttm)	-3.37
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,111,023
Open	11.80
Previous Close	11.80
Day's Range	11.25 - 12.00
52-Week Range	10.72 - 47.45
Beta	1.11
Analysts	Strong Buy
Price Target	47.73 (+316.86%)
Earnings Date	May 1, 2025

About DYN

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutic...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 17, 2020
• Employees: 191
• Stock Exchange: NASDAQ
• Ticker Symbol: DYN
• Website: https://www.dyne-tx.com

Analyst Forecast

According to 12 analysts, the average rating for DYN stock is "Strong Buy." The 12-month stock price forecast is $47.73, which is an increase of 316.86% from the latest price.

Price Target

$47.73

(316.86% upside)

Analyst Consensus: Strong Buy